Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
eqs_en 
0 12.06.24
EQS-News: Evotec SE: Results of the Annual General Meeting 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE: Results of the Annual General Meeting 2024
EQS-News: Evotec SE: Results of the Annual General Meeting 2024
eqs_en 
0 10.06.24
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
eqs_en 
0 06.06.24
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
eqs_en 
0 30.05.24
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
eqs_en 
0 28.05.24
EQS-News: Evotec reports Q1 2024 results and provides corporate update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec reports Q1 2024 results and provides corporate update
EQS-News: Evotec reports Q1 2024 results and provides corporate update
eqs_en 
0 22.05.24
EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024
EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024
eqs_en 
0 15.05.24
EQS-News: Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effectshttp://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
EQS-News: Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effects
EQS-News: Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effects
eqs_en 
0 08.05.24
EQS-News: Bayer and Evotec collaborate to advance precision cardiology: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Bayer and Evotec collaborate to advance precision cardiology
EQS-News: Bayer and Evotec collaborate to advance precision cardiology
eqs_en 
0 30.04.24
EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
eqs_en 
0 29.04.24
EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
eqs_en 
0 24.04.24
EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth
EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth
eqs_en 
0 24.04.24
EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
eqs_en 
0 23.04.24
EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
eqs_en 
0 23.04.24
EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
eqs_en 
0 18.04.24
EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024
EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024
eqs_en 
0 17.04.24
EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer
EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer
eqs_en 
0 17.04.24
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
eqs_en 
0 11.04.24
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
eqs_en 
0 22.03.24
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
eqs_en 
0 13.03.24
EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
eqs_en 
0 07.03.24
EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
eqs_en 
0 06.03.24
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
eqs_en 
0 09.02.24
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
eqs_en 
0 07.02.24
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
eqs_en 
0 05.02.24